제브라 테라퓨틱스(ZVRA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $11.61 (-1.94%), 시가총액 $0.62B, PER (주가수익비율) 5.22, 52주 최저~최고 $7.23 ~ $12.79.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactiv
제브라 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
제브라 테라퓨틱스의 현재 주가는 $11.61 (-1.94%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
제브라 테라퓨틱스의 시가총액은 약 $0.62B입니다. PER은 5.22입니다.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activa